Sykehuset Østfold HF er et sykehus som har enheter på Kalnes, i Fredrikstad, Moss, Sarpsborg og Halden. Sykehuset eies av Helse Sør-Øst. Det meste av virksomheten er samlet på Sykehuset Østfold Kalnes.

During the past decade, Sykehuset Østfold Kalnes conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 4 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sykehuset Østfold Kalnes" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Anthos Therapeutics, Inc." with 2 trials sponsored, "Oslo University Hospital" with 1 trials sponsored, "Region Örebro County" with 1 trials sponsored and "Rigel Pharmaceuticals" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sykehuset Østfold Kalnes" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Itreas" with 2 trials as a collaborator, "Lovisenberg Diakonale Hospital" with 2 trials as a collaborator, "Aalborg University" with 1 trials as a collaborator and "Alesund Hospital" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Sykehuset Østfold Kalnes" are "Deep Venous Thrombosis" (2 trials), "Heart Failure" (2 trials), "Pulmonary Embolism" (2 trials), "Venous Thromboembolism" (2 trials) and "Clostridium Difficile Infection" (1 trials). Many other conditions were trialed in "Sykehuset Østfold Kalnes" in a lesser frequency.

Most popular intervention types in "Sykehuset Østfold Kalnes" are "Drug" (9 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Abelacimab" (2 trials), "Empagliflozin" (2 trials), "Apixaban" (1 trials) and "Cytarabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sykehuset Østfold Kalnes" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Sykehuset Østfold Kalnes". undefined are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Sykehuset Østfold Kalnes, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sykehuset Østfold Kalnes, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".